What Caught Our Eye (WCOE), March 10, 2017
What Caught Our Eye is our week-in-review blog series, where we recap the cancer policy articles, studies, and stories that caught our attention.

Affordable Care Act

Replacement Bill Introduced In Congress

The American Health Care Act (AHCA) was introduced in the House earlier this week. A great deal has been written analyzing this legislation, and so we only highlight a few articles here looking at different aspects.

A thorough summary of the legislation:

A breakdown of the premium cost changes:

CBPP Analysis of the Bill

The Center on Budget and Policy Priorities has a lot of excellent analysis on the AHCA. This article highlights the fact that “in 11 states, tax credits would be cut more than in half” to help people pay their premiums. It also states: “Consumers’ costs would probably increase even more than tax credits would fall, since the House plan would likely cause individual market premiums to rise.”

ACA Support Continues to Climb

While repeal and replacement of the ACA is being debated, the law is seeing some of its highest support on record.

Cancer Policy

The Reality of Cancer Care

STAT News has an honest and sobering article about the need to “do better in communicating the reality of cancer care to patients.”

Cancer drugs are all too often hailed as miracles, breakthroughs, game-changers, or even cures, even when they are no such thing. We recently reported in JAMA Oncology that these words were used 50 percent of the time to describe drugs not approved by the FDA, and 14 percent of the time to describe drugs that had only worked in mice.

Palliative Care

Palliative care is still misunderstood, often incorrectly equated to end-of-life care or hospice. Palliative and end-of-life care must be seen as two different types of care, each offering distinct benefits for cancer patients when appropriate. “How and when people are referred to palliative care should be prioritised according to cancer patients, a new study in the Oncology Nursing Forum has found.”

Coping With Cancer

Some Patients Discontinuing Highly-Effective CML Drug

A drug used to treat Chronic Myelogenous Leukemia (CML) has been so effective that some doctors now discuss discontinuing treatment with certain patients.

Imagine you had a life-threatening cancer that a wonder drug had kept in remission for years. Would you risk quitting? Thousands of people with a blood cancer called chronic myelogenous leukemia, or CML, now have that choice.

More From “What Caught Our Eye” »

Follow us on Twitter: @canceradvocacy